Browse our anti-FFAR1 (FFAR1) Antibodies

Human Free Fatty Acid Receptor 1 (FFAR1) interaction partners

1. Data indicate that 20-HETE and FFAR1 function together in a positive feedback loop to enhance glucose-stimulated insulin (show INS Antibodies) secretion (GSIS).

2. Comparison with an additional 2.2-A structure of the human GPR40-MK-8666 binary complex reveals an induced-fit conformational coupling between the partial agonist and AgoPAM binding sites, involving rearrangements of the transmembrane helices 4 and 5 (TM4 (show TPM4 Antibodies) and TM5) and transition of the intracellular loop 2 (ICL2) into a short helix.

3. Results show that GPR40 negatively regulated the cell motile and invasive activities of HT1080 (show CDC123 Antibodies) cells suggesting that GPR40 negatively regulates the tumor progression of fibrosarcoma cells.

4. Brain free long-chain fatty acids-GPR40/FFA1 signaling might have an important role in the modulation of endogenous pain control systems. (review)

5. It regulates insulin (show INS Antibodies) secretion in pancreatic beta-cells. (review)

6. Data from molecular docking simulations suggest that the binding pocket of GPR40 exhibits binding of free fatty acids (FFA) with chain lengths of C15 or fewer; for FFA with lengths longer than C15, part of alkyl chain extends out of binding pocket.

7. GPR120 (show O3FAR1 Antibodies) negatively and GPR40 positively regulate cellular functions during tumor progression in lung cancer cells.

8. Increased membrane permeability induced by linoleic acid is mediated by an intracellular signaling pathway activated by GPR40 that leads to an increase in membrane levels of Cx43 (show GJA1 Antibodies) phosphorylated at serine 373 via Akt (show AKT1 Antibodies).

9. These data demonstrate that R104 in GPR40 is critically involved in the normal receptor functions. Interestingly, R104P is a registered single-nucleotide polymorphism of GPR40.

10. Characterizing pharmacological ligands to study the long-chain fatty acid receptors GPR40/FFA1 and GPR120 (show O3FAR1 Antibodies)/FFA4

Mouse (Murine) Free Fatty Acid Receptor 1 (FFAR1) interaction partners

1. We found that FFAR1-/- female mice showed significant impairments in maternal behavior, and exhibited an emotionally altered behavior, when compared to WT mice. Our findings suggest that the dysfunction of brain PUFA-GPR40/FFAR1 signaling might induce damage to emotional and maternal behavior in female mice.

2. GPR120 (show O3FAR1 Antibodies) suppresses adipose tissue lipolysis and synergizes with GPR40 in antidiabetic efficacy

3. GPR40 and (GPR120 (show O3FAR1 Antibodies)) act in concert in the hypothalamus to reduce energy efficiency and regulate the inflammation associated with obesity.

4. GPR40 role in the bone loss

5. These findings suggested that dysfunction of the GPR40/FFAR1 signaling pathway altered the endogenous pain control system and that this dysfunction might be associated with the development of chronic pain.

6. Together, our data indicate effects of AgoPAMs that go beyond glucose lowering previously observed with GPR40 partial agonist treatment with additional potential for weight loss.

7. These results support the hypothesis that mercaptoacetate stimulates food intake by blocking fatty acid effects on GPR40.

8. These results indicated that GPR120 (show O3FAR1 Antibodies) enhanced and GPR40 inhibited the cell motile activity of highly migratory osteosarcoma cells.

9. Results suggest that brain GPR40/FFAR1 is associated with anxiety- and depression-related behavior regulated by the increment of noradrenaline in the brain.

10. Data revealed a weak influence of GPR40 agonist on osteoblast markers expression. Nevertheless, a significant increase in OPG (show TNFSF11 Antibodies) expression was observed upon GW9508 treatment that contribute to explain the GPR40-related osteoporosis prevention